Abstract
Cox-2 inhibitors have been identified as promising candidates for cancer therapy. Several studies have recently proposed the use of celecoxib in long-term low-intensity chemotherapy protocols for recurrent tumors. However, drug-induced hypersensitivity reactions may force discontinuation of the medication and, thus, significantly complicate successful care. Here, we report on celecoxib desensitization after a celecoxib-induced skin reaction, thereby allowing the continuation of temozolomide/celecoxib chemotherapy in a young patient with recurrent astrocytoma.
MeSH terms
-
Adult
-
Antineoplastic Agents, Alkylating / adverse effects
-
Antineoplastic Agents, Alkylating / immunology
-
Antineoplastic Agents, Alkylating / therapeutic use*
-
Astrocytoma / drug therapy
-
Celecoxib
-
Cyclooxygenase 2 Inhibitors / adverse effects*
-
Cyclooxygenase 2 Inhibitors / immunology
-
Cyclooxygenase 2 Inhibitors / therapeutic use*
-
Dacarbazine / analogs & derivatives*
-
Dacarbazine / therapeutic use
-
Desensitization, Immunologic / methods*
-
Drug Hypersensitivity / etiology
-
Drug Hypersensitivity / immunology
-
Drug Hypersensitivity / therapy*
-
Humans
-
Male
-
Pyrazoles / adverse effects*
-
Pyrazoles / immunology
-
Pyrazoles / therapeutic use*
-
Sulfonamides / adverse effects*
-
Sulfonamides / immunology
-
Sulfonamides / therapeutic use*
-
Temozolomide
-
Young Adult
Substances
-
Antineoplastic Agents, Alkylating
-
Cyclooxygenase 2 Inhibitors
-
Pyrazoles
-
Sulfonamides
-
Dacarbazine
-
Celecoxib
-
Temozolomide